Evidence map›Paper›PMID 32106854›Full record

ArticleHarm reduction journal2020

Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.

Anna Palmer, Nick Scott, Paul Dietze, Peter Higgs

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Harm reduction journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Ketamine enhancement of dexmedetomidine attenuation of methamphetamine-induced agitation in rats.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The influence of drug class on reward in substance use disorders.Pharmacology, biochemistry, and behavior · 2024
    Review
  14. Article
  15. Article
  16. Goofball Polypharmacy.The Journal of pharmacology and experimental therapeutics · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anna PalmerBehaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia. anna.palmer@burnet.edu.au.
Nick ScottBehaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia.
Paul DietzeBehaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia.
Peter HiggsBehaviours and Health Risks Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia.ORCID 0000-0002-5587-5379
Burnet Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe report on motivations for crystal methamphetamine-opioid co-use/co-injection through narratives of people who inject drugs during a period of increased crystal methamphetamine use reporting in Australia.

methodsFourteen in-depth interviews were undertaken with selected participants (12 male, 2 female) from the Melbourne Injecting Drug User Cohort Study, including those in and out of opioid substitution therapy (OST).

resultsThe main motivations for co-use reported by participants were as follows: (1) that heroin could be used to reduce the negative side effects of heavy crystal methamphetamine use, particularly during the 'comedown' phase; (2) that small quantities of crystal methamphetamine used with heroin could prolong the intoxication effect of heroin, and hence the time before opioid withdrawal; (3) that co-injection of crystal methamphetamine and heroin produced a more desirable intoxication effect than using either substance on its own and; (4) that crystal methamphetamine provided a substitute 'high' for heroin after commencing OST treatment.

conclusionsCo-use of methamphetamine and opioids has been used by people who inject drugs to facilitate intoxication, sometimes as the result of ineffective opioid substitution therapy (OST) treatment and perceived lack of pleasure after stabilisation on OST treatment.

Indexed as

MotivationAdultAmphetamine-Related DisordersAnalgesics, OpioidAustraliaCohort StudiesComorbidityEvaluation Studies as TopicFemaleHumansInterviews as TopicMaleMethamphetamineOpioid-Related DisordersSubstance Abuse, IntravenousAnalgesics, OpioidMethamphetamineCo-injectionHarm reductionInjecting drug useMethamphetamineOpioidsOpioid substitution therapyPolydrug useQualitative

Identifiers

PMID32106854
PMCPMC7047412
OpenAlexW3009977114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.